Invesaro

Stocks Health care MEDP

NASDAQ · Health care

Medpace Holdings, Inc. (MEDP)

Medpace Holdings, Inc. brought in $2.8B of revenue over the twelve months to June 30, 2026, up 24.7% from a year earlier. Net income was $491.5M, a net margin of 17.7%. Operating cash flow minus capital spending left $681.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $502.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 23, 2026.

Price
$618.88
-0.28% on the day · September 25, 2026
52-week range $373.00 to $677.90
Market cap
$17.3B
Revenue (last 12 months)
$2.8B
+24.7% year on year
Net margin
17.7%
P/E
40.5
on FY2025 diluted EPS

What Medpace Holdings, Inc. does

Medpace Holdings, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker MEDP.

Revenue and profit by year

Revenue
FY18: $704.6M $704.6M FY18FY19: $861M $861M FY19FY20: $925.9M $925.9M FY20FY21: $1.1B $1.1B FY21FY22: $1.5B $1.5B FY22FY23: $1.9B $1.9B FY23FY24: $2.1B $2.1B FY24FY25: $2.5B $2.5B FY25
Net income
FY18: $73.2M $73.2M FY18FY19: $100.4M $100.4M FY19FY20: $145.4M $145.4M FY20FY21: $181.8M $181.8M FY21FY22: $245.4M $245.4M FY22FY23: $282.8M $282.8M FY23FY24: $404.4M $404.4M FY24FY25: $451.1M $451.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.5B$534.9M$451.1M$15.28$681.9M
2024$2.1B$446.9M$404.4M$12.63$572.3M
2023$1.9B$336.8M$282.8M$8.88$396.7M
2022$1.5B$278.7M$245.4M$7.28$351.2M
2021$1.1B$198.6M$181.8M$4.81$235.1M
2020$925.9M$167M$145.4M$3.84$227.3M

Latest SEC filings

What Medpace Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
    Passive stake (5% or more) SCHEDULE 13G
  2. July 23, 2026
    Quarterly report 10-Q · period to June 30, 2026
  3. July 22, 2026
    Quarterly results 8-K
  4. June 4, 2026
    Executive or director change 8-K
  5. May 19, 2026
    Bylaws or fiscal year changed 8-K
  6. April 23, 2026
    Quarterly report 10-Q · period to March 31, 2026
  7. April 22, 2026
    Quarterly results 8-K
  8. April 1, 2026
    Additional proxy material DEFA14A
  9. April 1, 2026
    Proxy statement DEF 14A
  10. April 1, 2026
    Annual report to shareholders ARS

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 25, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about MEDP

What does Medpace Holdings, Inc. do?

Medpace Holdings, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker MEDP.

Is Medpace Holdings, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $491.5M on revenue of $2.8B, a net margin of 17.7%.

How much revenue does Medpace Holdings, Inc. make?

Over the twelve months to June 30, 2026 Medpace Holdings, Inc. reported revenue of $2.8B. That is 24.7% more than a year earlier.

When did Medpace Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 23, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.

Similar companies

IQV
Iqvia Holdings Inc.
ICLR
Icon PLC
INCY
Incyte Corp
CRL
Charles River Laboratories International, Inc.
NOTVQ
Inotiv, Inc.
NRC
Nrc Health

Follow MEDP

Get an email when Medpace Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow MEDP: get an email when it files

Where the numbers come from

Financial figures are the values Medpace Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.